Rayya Talks Returns with Gut Health Expert Joy Somers for an Empowering Wellness Morning
DUBAI, DUBAI, UNITED ARAB EMIRATES, June 4, 2025 / EINPresswire.com / -- MGallery the Retreat, Palm Dubai is pleased to announce the upcoming edition of Rayya Talks, set to take place on Thursday, 12 June 2025. This empowering morning experience will be led by certified Holistic Transformation Coach and Gut Health Expert Joy Somers, and will feature a first-of-its-kind lymphatic flow workout and sound healing session to complement the wellness journey.
This morning session is themed 'The Gut Glow-Up: Detox, Drain & Drop the Weight,' the event invites women to reconnect with their bodies through the transformative power of gut health, natural detox and energy recalibration. This immersive wellness session integrates movement, nourishment, education and stillness for full-body healing and rejuvenation.
Guests will begin with a 45-minute gut health masterclass led by Joy Somers, where they will uncover how gut health, metabolism, and the lymphatic system work in synergy to support vibrant skin, healthy weight, and mental clarity.
This will be followed by a 35-minute guided lymphatic detox workout, curated and led by Joy herself - marking the first time this method is offered in a live group setting in the UAE. The low-impact, flow-based movement sequence is designed to activate the lymphatic system, reduce inflammation, and stimulate natural detoxification.
The morning concludes with a 25-minute sound bath experience facilitated by renowned sound healer Micaela Arruda, inviting participants to ground, integrate and restore inner calm.
'At MGallery the Retreat Palm Dubai, our goal is to offer experiences that go beyond wellness trends and truly empower our guests. Rayya Talks embodies this mission, and we are honoured to welcome Joy Somers for a morning that speaks to the mind, body, and soul,' said Samir Arora, General Manager, MGallery the Retreat Palm Dubai.
'The gut is the body's command center. When it functions optimally, your energy, immunity, and confidence return,' said Joy Somers. 'This session is about equipping women with the knowledge and tools to detox safely, move with intention, and feel at home in their bodies again.'
Event Details:
Date: Thursday 12 June 2025
Time: 9:30 AM – 11:30 AM
Venue: Club Lounge, MGallery the Retreat Palm Dubai
Dress Code: Activewear
Price: AED 180 per person
Itinerary:
● 45 min Gut Health Masterclass with Joy Somers
● 35 min Lymphatic Detox Workout (First-of-its-kind session)
● 25 min Sound Bath with Micaela Arruda
● Includes nourishing bites, detox juices, coffee, tea and Glow-Up Protein Coffees sponsored by Chief Collagen
● All attendees will leave with a carefully curated goodie bag by Joy Somers
This unique experience is designed for women seeking real change - physically, emotionally, and energetically. Limited spots are available.
For more information and for booking https://pay.ziina.com/coachjoyous05/T2FKXVIdH or follow both @coachjoyous05l and @theretreatpalmdubai on instagram.
(ends)
PR Contact:
Gemma L'Appanna Founder and CEO, L'Atelier Consulting
Email: [email protected]
Phone: +971 555163914
About MGallery The Retreat Palm Dubai
The Retreat Palm Dubai is Dubai's first 5-star family-friendly wellness resort. Nestled on the iconic Palm Jumeirah, the resort offers a tranquil haven where guests can rejuvenate and relax amidst stunning beachfront views. With a focus on holistic wellness, The Retreat Palm Dubai provides a range of wellness activities, world-class dining options, and luxurious accommodations.
About Joy Somers:
Joy Somers is a certified Holistic Transformation Coach and Gut Health Expert with over a decade of experience in guiding individuals toward sustainable wellness. Her integrative approach combines gut-healing nutrition, hormone balance, and modern biohacking strategies to help clients achieve lasting health transformations.
Having coached over 10,000 busy professionals, Joy specialises in helping individuals lose weight, boost energy, and overcome chronic symptoms without restrictive dieting or excessive supplementation. Her programs emphasize natural methods to reset metabolism, balance hormones, and enhance overall vitality.
Joy's background includes international competition in CrossFit and powerlifting, reflecting her commitment to physical fitness and resilience. She is also the creator of the popular 10-Day Gut Health Transformation Program, designed to help participants reset their digestive health and metabolism safely and effectively.
Based in Dubai, Joy is a sought-after speaker and coach, known for her relatable and empowering approach to wellness. She is passionate about making gut health accessible and achievable for all, helping clients feel energised, confident and in control of their health.
Gemma LAppanna
L'Atelier Public Relations
+ +971 55 516 3914
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 days ago
- Business Upturn
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
San Francisco Chronicle
6 days ago
- San Francisco Chronicle
Nina Kuscsik, marathon pioneer and first (official) winner of Boston women's race, has died
BOSTON (AP) — Nina Kuscsik, who campaigned for women's inclusion in long-distance running and then won the Boston Marathon the first year that they were officially allowed to enter into the race, has died. She was 86. An obituary for the A.L. Jacobsen Funeral Home in Huntington Station, New York, said Kuscsik died June 8 of respiratory failure after a long battle with Alzheimer's disease. 'Nina was more than a pioneer, determined women's running advocate, and celebrated icon within the sport. To us, she was a friend who will always be remembered for her kindness, joyful laugh and smile,' the Boston Athletic Association said on Instagram. 'Nina held the distinct honor of winning the 1972 Boston Marathon, and recognized the platform that came with that triumphant moment, inspiring thousands of women to reach their own goals and finish lines in the decades since. The BAA extends heartfelt condolences to Nina's family, friends, and all in the running community who were touched by her grace.' According to the obituary, Kuscsik graduated from high school at 16, studied nursing for two years and received her license at 18 after petitioning to change a New York law that required nurses to be 21. She won state championships in speed skating, roller skating and cycling – all in the same year -- before turning to running when her bicycle broke. She ran the Boston Marathon four times from 1968-71 — before women were officially welcomed, a period retroactively recognized as the Pioneer Era — and then won the first official women's race in 1972. She was also the first woman to enter the New York race, in 1970, and was one of the 'Six who Sat' – six women who refused to start the '72 New York City Marathon for 10 minutes to protest an Amateur Athletic Union rule that the women's race had to be separate from the men's. She won that year and the next year as well. She later served on AAU and USA Track and Field committees drafting rules for women's running. Kathrine Switzer, who entered the 1971 Boston Marathon using her initials and became the first woman to official compete, called Kuscsik 'one of our greatest leaders.' 'Nina was not only a champion runner, but was instrumental in the official acceptance of women and distance running because she did years of tough work of changing rules, regulations and submitting medical evidence to prove women's capability," said Switzer, who started alongside Kuscsik and six other women who met the qualifying time for the the 1972 Boston race. 'Eight of us registered, eight of us showed up, and all eight of us finished,' she said. 'It was a stunning moment — and a blistering hot day — but appropriately enough, Nina won.' In addition to the more than 80 marathons she ran over her lifetime, Kuscsik set the American record for the 50-mile run in 1977 and won the Empire State Building Run-Up three straight years from 1979–81.
Chicago Tribune
6 days ago
- Chicago Tribune
Nina Kuscsik, a marathon pioneer and 1st official winner of Boston women's race, dies at 86
BOSTON — Nina Kuscsik, who campaigned for women's inclusion in long-distance running and then won the Boston Marathon the first year they were officially allowed to enter the race, has died. She was 86. An obituary for the A.L. Jacobsen Funeral Home in Huntington Station, N.Y., said Kuscsik died June 8 of respiratory failure after a long battle with Alzheimer's disease. 'Nina was more than a pioneer, determined women's running advocate and celebrated icon within the sport. To us, she was a friend who will always be remembered for her kindness, joyful laugh and smile,' the Boston Athletic Association said on Instagram. 'Nina held the distinct honor of winning the 1972 Boston Marathon and recognized the platform that came with that triumphant moment, inspiring thousands of women to reach their own goals and finish lines in the decades since. The BAA extends heartfelt condolences to Nina's family, friends and all in the running community who were touched by her grace.' According to the obituary, Kuscsik graduated from high school at 16, studied nursing for two years and received her license at 18 after petitioning to change a New York law that required nurses to be 21. She won state championships in speed skating, roller skating and cycling — all in the same year — before turning to running when her bicycle broke. She ran the Boston Marathon four times from 1968-71 — before women were officially welcomed, a period retroactively recognized as the Pioneer Era — and then won the first official women's race in 1972. She was also the first woman to enter the New York race in 1970 and was one of the 'Six Who Sat' — six women who refused to start the '72 New York City Marathon for 10 minutes to protest an Amateur Athletic Union rule that the women's race had to be separate from the men's. She won that year and the next year as well. She later served on AAU and USA Track and Field committees drafting rules for women's running. Kathrine Switzer, who entered the 1971 Boston Marathon using her initials and became the first woman to officially compete, called Kuscsik 'one of our greatest leaders.' 'Nina was not only a champion runner but was instrumental in the official acceptance of women in distance running because she did years of tough work of changing rules, regulations and submitting medical evidence to prove women's capability,' said Switzer, who started alongside Kuscsik and six other women who met the qualifying time for the the 1972 Boston race. 'Eight of us registered, eight of us showed up and all eight of us finished. It was a stunning moment — and a blistering hot day — but appropriately enough, Nina won.' In addition to the more than 80 marathons she ran over her lifetime, Kuscsik set the American record for the 50-mile run in 1977 and won the Empire State Building Run-Up three straight years from 1979-81. She was inducted into the Long Distance Running Hall of Fame in 1999.
